FDA Approaches Full Disclosure For Advisory Panel Member Conflicts
This article was originally published in The Gray Sheet
Executive Summary
FDA plans to disclose the extent of advisory panel members' conflicts of interest at future panel meetings under a level one draft guidance issued Feb. 1